Print Email Facebook Twitter Tumor necrosis factor-α plays an important role in restenosis development Title Tumor necrosis factor-α plays an important role in restenosis development Author Monraats, P.S. Pires, N.M.M. Schepers, A. Agema, W.R.P. Boesten, L.S.M. de Vries, M.R. Zwinderman, A.H. de Maat, M.P.M. Doevendans, P.A.F.M. de Winter, R.J. Tio, R.A. Waltenberger, J. 't Hart, L.M. Frants, R.R. Quax, P.H.A. van Vlijmen, B.J.M. Havekes, L.M. van der Laarse, A. van der Wall, E.E. Jukema, J.W. TNO Kwaliteit van Leven Publication year 2005 Abstract Genetic factors appear to be important in the restenotic process after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. TNFα, a key regulator of inflammatory responses, may exert critical influence on the development of restenosis after PCI. The GENetic DEterminants of Restenosis (GENDER) project included 3104 patients who underwent a successful PCI. Systematic genotyping for six polymorphisms in the TNFα gene was performed. The role of TNFα in restenosis was also assessed in ApoE*3-Leiden mice, TNFα knockout mice, and by local delivery of a TNFα biosynthesis inhibitor, thalidomide. The -238G-1031T haplotype of the TNFα gene increased clinical and angiographic risk of restenosis (P=0.02 and P=0.002, respectively). In a mouse model of reactive stenosis, arterial TNFα mRNA was significantly time-dependently up-regulated. Mice lacking TNFα or treated locally with thalidomide showed a reduction in reactive stenosis (P=0.01 and P=0.005, respectively). Clinical and preclinical data indicate that TNFα plays an important role in restenosis. Therefore, TNFα genotype may be used as a risk marker for restenosis and may contribute to individual patient screening prior to PCI in clinical practice. Inhibition of TNFα may be an anti-restenotic target strategy. ©FASEB. Chemicals / CAS: thalidomide, 50-35-1; RNA, Messenger; Thalidomide, 50-35-1; Tumor Necrosis Factor-alpha Subject Biology HealthBiomedical ResearchHaplotypeTNFαTransgenic miceApolipoprotein E3Messenger RNAThalidomideTumor necrosis factor alphaAdultAgedAngiographyAnimal experimentAnimal modelClinical practiceDisease markerDrug delivery systemGenetic polymorphismHeredityKnockout mouseNonhumanPercutaneous coronary interventionRestenosisRisk assessmentScreeningAgedAllelesAngina PectorisAngiographyAngioplasty, Transluminal, Percutaneous CoronaryAnimalsConstriction, PathologicCoronary AngiographyCoronary DiseaseCoronary RestenosisDisease Models, AnimalFemaleFemoral ArteryGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenotypeHaplotypesHumansInflammationIschemiaLinkage DisequilibriumMaleMiceMice, KnockoutMice, TransgenicMiddle AgedMultivariate AnalysisOdds RatioPolymorphism, GeneticRegression AnalysisReverse Transcriptase Polymerase Chain ReactionRisk FactorsRNA, MessengerThalidomideTreatment OutcomeTumor Necrosis Factor-alphaUp-RegulationAnimaliaMus musculus To reference this document use: http://resolver.tudelft.nl/uuid:11506bee-65f4-4c8d-9f02-23c7c8aeb89b DOI https://doi.org/10.1096/fj.05-4634com TNO identifier 238864 ISSN 0892-6638 Source FASEB Journal, 19 (14), 1998-2004 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.